

About IntelGenx Corp.

IntelGen_x Corp.

Founded in June 2003, IntelGenx Technologies Corp. ("IntelGenx") is a Montreal-based drug delivery company focused on novel oral controlled release technologies. IntelGenx has developed three proprietary technologies, a Tri-Layer Tablet "VersaTab", a Mucoadhesive Tablet "AdVersa", and an oral film "VersaFilm", which enable the company to customize the release profile of orally administered drugs and maximize their therapeutic effect.


www.intelgenx.com

Corporate Info

Symbol: OTCBB: IGXT
TSX-V: IGX
Shares Out: Basic: 49 million
Fully Diluted: 69 million
Recent Share Price: \$0.54


Technologies

Tri-Layer technology "VersaTab" represents a new generation of controlled release tablets that uses a layering technique to modulate the release of active compounds. The technology is based on a Tri-Layer tablet with an active core layer and two easily disintegrating cover layers.



- Superior alternative to conventional delivery systems
- Broad range of delivery profiles
- Significant manufacturing cost savings

Oral film technology "VersaFilm" is the application system of choice for conditions requiring rapid acting medication such as migraines, motion sickness and nausea.



- Instant release of drug
- Bypasses GI tract, advantageous for drugs having GI side effects
- Avoids/reduces loss of concentration of the drug before it reaches the circulation system
- Ideal for lifecycle management
- FDA approved for pharmaceutical products

Mucoadhesive Tablet technology "AdVersa" provides controlled release of medication to the oral mucosa.



- Intended for buccal or sublingual delivery
- Variable residence time - immediate or slow release of the drug
- Release of the drug not requiring chewing or water

Recent Highlights

2011-12-21

Development & Commercialization Agreement with Par Pharmaceutical

2011-11-11

FDA Approval of High Dose Anti-Depressant CPI-300

22/06/2011

Closing of Private Placements

Management

Dr. Horst Zerbe, Ph.D.

Chairman and CEO

Paul A. Simmons, AFCA

Chief Financial Officer

Nadine Paiement, M.Sc.

Director, Pharmaceutical R&D

Cormac Long Ph.D.

Director of Corporate Development

Directors

Dr. Horst G. Zerbe

Chairman and CEO, IntelGenx

J. Bernard Boudreau, QC, PC


Dr. Rajiv Khosla, MBA

**John S. Marinucci, C.A., ICD.D,
H.R.C.C.C.**

Bernd J. Melchers, CFA

Ian Troup, B.Sc.

Product Pipeline



* Anticipated
** FDA Approval

● 505(b)(2)

Upcoming Milestones

- Q1, 2012 Finalize licensing agreement for CPI-300
- Q1, 2012 Execute definitive agreement for new Animal Health development and licensing VersaFilm project
- Q2/3, 2012 Commercial launch of CPI-300
- Q2, 2012 Complete pivotal biostudy for anti-migraine VersaFilm
- Q4, 2012 Submit 505(b)(2) NDA for anti-migraine VersaFilm

Investment Highlights

- Unique drug delivery technologies
- Patented technology and strong Intellectual Property portfolio
- Broad product pipeline
- First product commercialized 11/2008
- Addressing multi-billion dollar markets
- Strong management and key scientific expertise
- Strategic R&D and commercial partnerships in place

Contact Info

IntelGenx Corp.

6425 Abrams, St-Laurent (Qc) H4S 1X9
Telephone: 514-331-7440
Fax: 514-331-0436
E-mail: info@intelgenx.com

Investor Relations - Canada

Hogan Mullally
SectorSpeak Inc., Winnipeg, Manitoba
Tel: 204-479-2516
hogan@sectorspeak.com

Investor Relations - USA

Jeffrey Benison
Little Gem Life Science Partners, New York, NY
Tel: 212-334-8709
jeffrey@littlegem.us

Public Relations

Beverly Brooks
Kingsdale Communications Inc., Toronto, ON
Tel: 416-867-4550
bbrooks@kingsdalecommunications.com

Delivering Technology to the Pharmaceutical Industry **IntelGenx** Corp.

Copyright © 2006 IntelGenx Corp. All rights reserved